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Background: Pleural effusions can be caused by highly different underlying diseases and are characterized by
complex interactions of various local and circulating cells as well as numerous soluble parameters like interleukins
(IL). Knowledge of this complex network can be helpful in order to make the differential diagnosis in known
malignant pleural effusions and understand the underlying immunochemistry of each disease or condition.
Methods: We investigated immunoreactive concentrations of Interleukin 10 (IL-10) and Interleukin 17 (IL-17) in
malignant pleural effusions and peripheral blood from patients with bronchial carcinomas and other carcinomas,
excluding other conditions such as congestive heart failure (CHF) and pneumonias in twenty four (24) patients (9 men/
15 women), 37-74 years (mean:61) with already diagnosed malignant pleural effusions applying the ELISA method.
Results: The SPSS 15 program for Windows was used. Quantitative analysis showed high concentrations of IL-10 and
IL-17 in pleural fluid and blood. Even though IL-17 levels -both blood and pleural- were lower than IL-10’s, statistical
correlation between blood and pleural concentations was proven, confirming once more the systematic action of
these cytokines. At the same time high IL-17 levels in malignant effusions shows maybe a new perspective in
understanding the pathophysiology of malignant pleural effusions.
Conclusions: Our results confirm the pathogenetic role of these cytokines in malignant pleural effusions combining
for the first time a pro- and an anti- inflammatory cytokine. The observation that IL-17 is elevated in malignant pleural
effusions may give a new meaning in Virchow’s remarks 100 years ago. Larger number of patients is needed to confirm
our hypothesis.Background
Pleural effusions are common clinical problems, occuring
in more than 1 million patients each year. Up to 22% of
these effusions are caused by malignant disease and more
than 100.000 malignant effusions require treatment
annually. [1] Affected patients with advanced neoplastic
disease experience considerable morbidity.
Pleural effusion results from a derangement in the
normal physiology such that there is increased production
of pleural fluid or a change in its composition with or
without a reduction in the absorption of the fluid. It can
result from primary or secondary tumors of the pleura,
with seeding of the intrapleural space and lymphatic
obstruction. Free-floating tumor cells block absorption of* Correspondence: klimas2005@yahoo.com
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distribution, and reproduction in any mediumfluid and produce vasoactive substances that in turn
increase the production and block the absorption of
intrapleural protein and fluid.
In adults, 95% of neoplastic pleural effusions arise
from a metastatic source, with lung and breast carci-
noma accounting for 75% of all cases. Other common
causes are lymphoma, gastric cancer, and ovarian cancer.
About half of patients with breast cancer develop a
pleural effusion within their lifetime, compared with one
fourth of patients with lung cancer and one third of
patients with lymphoma.
Most pediatric effusions, on the other hand, are
benign. If malignant, lymphomas or leukemias account
for half, with the remainder a mix of tumors such as
neuroblastoma, Wilms’ tumor, and germ cell neoplasms.
Light’s criteria [2] are the golden standard regarding
the diagnosis of pleural effusion being a transudate or an
exudate. In many occasions though, these criteria aretral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Table 1 Descriptive statistics
N Minimum Maximum Mean Std. Deviation
IL- 17 B 24 18.258 31.605 23.63281 3.553243
IL-10 B 24 .00 112.43 13.8533 28.72131
IL-17 P 24 21.009 33.020 24.97380 3.595384
IL-10 P 24 1.75 229.83 60.1112 59.13965
WBC 24 2.3 30.6 10.296 5.5273
RBC 24 3.16 5.17 3.9788 .53680
HCT 24 28.4 46.5 36.192 4.7277
PLT 24 87 658 283.71 117.411
HB 24 9 16 12.02 1.675
GR% 24 43.5 93.8 71.912 10.7272
MONO% 24 .8 30.6 9.846 6.6490
LYMPH% 24 1.4 32.1 17.308 7.5535
AGE 24 37 74 60.42 10.270
GENDER 24 1 2 1.63 .495
AGEgroup 24 1 3 2.50 .659
primary1 24 1 2 1.63 .495
TYPE_3_UN 24 1 3 2.04 .624
chemo1yes 24 0 1 .58 .504
Valid N (listwise) 24
IL-17B Interleukin 17 levels in Blood, IL-10B Interleukin 10 levels in Blood,
IL-17P Interleukin 17 levels in Pleural Fluid, IL-10P Interleukin 10 levels in
Pleural Fluid, WBC White Blood Cells Count, RBC Red Blood Cells Count, HCT
Heamatocrit, PLT Platelets, HB Heamoglobulin, GR% Granulocytes percentage,
MONO% Monocytes percentage, LYMPH% Lymphocytes percentage, AGE Age,
GENDER Gender, AGEgroup 1 = age 1 to 39, 2 = 40 to 59, 3 = 60 and above,
Primary1 1 = Lung cancer, 2 = other, TYPE_3_UN 1 = NSCLC,SCLC,AdenoCa
Lung/2 = other malignancy/3 = Unknown origin of malignancy, chemo1yes
chemotherapy done = 1.
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even misclass an effusion e.g. when a patient is on diuretics
[3]. Pubmed search will reveal numerous attempts to
provide markers or measurements that will help us provide
a definite diagnosis or even a prognosis from a pleural
effusion.
Both immunocompetent cells and tumour cells secrete
cytokines, which have an important role in mediating
(down regulating and up regulating) cellular and
humoral activity [1].
Patients and methods
72 consecutive patients that had chest drain insertion or
pleural tap in the Thoracic surgery department were
included in the study over a period of 6 months.
All patients were consented for participating in this
study.
We measured the levels of Interleukins 10 and 17 in
patients with malignant pleural effusions. Patients were
included only if the effusion was an exudate and a definite
cytologic diagnosis of malignant cells in the pleural fluid,
was made.
Exclusion criteria included absence of malignant cells
in the cytology report, a definite diagnosis of effusion of
other origin (e.g. cardiac failure), pleural fluid was a
transudate or patients were under the treatment of
chemotherapy or corticosteroid therapy at the time of
the chest drain insertion or in the last three months.
All these conditions were excluded so as to minimize
the influence of them in the results.
24 patients fulfilled the above mentioned criteria 9 males
and 15 females, aged from 37 to 74 years (mean = 60)
(Table 1).
Pleural effusions were collected during the first diagnostic
or therapeutic thoracocentesis. Patients were consented
before the chest drain insertion for the research project.
The pleural fluid was placed in tubes containing ethylene
diamine tetra-acetate (EDTA) to a final concentration of
1 mg/ml. A separate portion was placed in plain tubes for
determination of LDH and total protein. Blood was
withdrawn from peripheral vein and collected in tubes
containing EDTA (final concentration 1 mg/ml) or in plain
tubes. The supernatants and cell pellets were separated by
centrifugation (600 g, 30 min, 4°C). Plasma, serum and
pleural effusion supernatants were aliquotted and stored at
−70°C for later analysis. All the collected samples were
tested within 1 month after collection. Positive and negative
controls were included in the assay.
Immunoreactive concentrations of IL-10 and IL-17 were
determined in effusion fluid and blood plasma samples
utilizing commercially available ELISA assays [TiterZymeW
EIA, ELISYS QUATRO, (IL-10)], [Quantikine, R&D
Systems GmbH, Wiesbaden, FRG (IL-17)]. The lower
detection limits were: IL-10 [3.75 pg/ml]; IL-17 [15 pg/ml].The cytokine level in the samples was determined by
ELISA method that used the quantitative sandwich enzyme
immunoassay technique.
Statistical analysis
Descriptive statistics were applied in every result. All
data are presented as mean + − standard error.
All variables were tested for normality of their distribu-
tion by the Shapiro test. For non-parametric quantitative
variables, data were subjected to Spearman analysis and
tested with Mann- Whitney U test. For parametric
variables, Pearson test was used for correlations. We
have used the SPSS 15 statistical package for Windows.
Statistical Significance was set to p <0.05.
Results
The mean values of all the measurements are presented
in Table 2. Interleukin’s 10 levels in blood ranged between
0–112.43 pg/ml, mean 13.85 pg/ml while Interleukin’s 17
blood levels were between 18.25 - 31.605 pg/ml mean
23.63 pg/ml. Il-17 pleural levels were between 21.00 pg/ml
Table 2 Concentrations of IL-10 and IL-17 in Pleural fluid














IL-10P levels of IL-10 in pleural fluid, IL-10B levels of IL-10 in Blood, IL-17P levels
of IL-17 in pleural fluid, IL-17B levels of IL-17 in Blood.
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-229.83 pg/ml with a mean 60.11 pg/ml.
9 out of 24 of the patients (37,5%) had chest cavity as
the primary site of malignancy, while all the rest were
considered as metastatic. In total 5 patients had meta-
static breast cancer, 2 had ovarian cancer, 1 neuroglioma,
1 lymphoma and 5 patients had metastatic pleural
disease from unknown primary origin. All patients had a
confirmed diagnosis with cytology analysis and Medical
Research Council (MRC) marked dyspnea 4 and 5 [4].
Quantitative analysis showed high concentrations of IL-10
and IL-17 in pleural fluid and blood. Interestingly enough,
levels of IL-17P were strongly correlated with the levels of
IL-17B (p = 0,000) (Table 3). Levels of IL-10B, IL-17B and
IL-17P didn’t differ significantly when comparing men and
women but levels IL-10P did differ (p = 0,037). Levels of
IL-17B were much higher in patients who had as primary
the chest cavity (p = 0,015) (Table 4).
Discussion
Management of malignant pleural effusions is a major
challenge. Large numbers of various variables and para-
meters exist and are useful weapons in our armamentarium
in the differential diagnosis of the origin in any pleural
effusion.Table 3 Correlations
IL −10 B (IL-10
Concentration
in Blood)
IL −10 B (IL-10 Concentration in Blood) -
IL −10 P (IL-10 Concentration in Pleural Fluid) P = 0,468
IL −17 B (IL-17 Concentration in Blood) P = 0,002
IL −17 P (IL-17 Concentration in Pleural Fluid) P = 0,166
WBC P = 0,508
RBC P = 0,896
HCT P = 0,615
PLT P = 0,438
HB P = 0,616
GRANULOCYTES% P = 0,285
MONOCYTES% P = 0,660
LYMPHOCYTES% P = 0,185Light’s criteria [2] are great in distinguishing the trans-
udates from the exudates. But, despite the numerous
bibliographic attempts they haven’t been prooven to be
sufficient in providing definite diagnosis. They were
proved to be not enough, not only in finding out when
an effusion was a malignant one or not, but also in the
differential diagnosis of the histopathology type regarding
the primary tumor. As a result, dozens of markers have
been tested all these years [1].
One of the latest additions in this differential diagnosis
marathon are cytokines. The complexity of the tumor
microenvironment is characterized by the presence of
multiple immune effector cells and a network of soluble
factors such as cytokines [5].
Cytokines are important signalling molecules in the
immune system. The immune response to foreign anti-
gens is based on the remarkable activities of a rather
small number of lymphocytes that specifically recognise
each antigen [6,7]. Cytokine levels are not just another
tool in distinguishing the type of malignancy but also a
very module in understanding the pathophysiology of
malignant pleural effusions and finally providing the evi-
dence needed in the design of new treatment approaches
for example cytokine specifically designed antibodies [8]
[9]. Since 1994 [10] has been found that Bronhogenic
Lung Cancer produces IL-10 and there were thoughts
that this might be the reason that the host defense was
suppressed. In 2000 De Vita et al. [11] showed that
patients with progressed disease of Small Cell Lung
Cancer had increased serum levels of IL-10 which, were
not associated with survival. A seminal paper regarding
the elevation of IL-10 in Thoracic malignancies is the
paper of Chen et al. [12] where the elevation of IL-10 in
malignant pleural effusions was shown to be statisticallyCorrelations
IL −10 P (IL-10
Concentration
in Pleural fluid)
IL −17 B (IL-17
Concentration
in Blood)
IL −17 P (IL-17
Concentration
in Pleural fluid)
P = 0,468 P = 0,002 P = 0,166
- P = 0,393 P = 0,224
P = 0,393 - P = 0,000
P = 0,224 P = 0,000 -
P = 0,888 P = 0,860 P = 0,877
P = 0,951 P = 0,761 P = 0,764
P = 0,992 P = 0,405 P = 0,433
P = 0,847 P = 0,308 P = 0,004
P = 0,699 P = 0,558 P = 0,410
P = 0,722 P = 0,559 P = 0,308
P = 0,449 P = 0,839 P = 0,433
P = 0,942 P = 0,404 P = 0,298
Table 4 Testing Interleukins levels with age (var = AGEGroups), primary lung cancer or not (var = primary1yes), had
chemotherapy or not in the last 6 months (chemo1yes)
IL −10 B (IL-10
Concentration
in Blood)
IL −10 P (IL-10
Concentration in
Pleural fluid)
IL −17 B (IL-17
Concentration
in Blood)
IL −17 P (IL-17
Concentration
in Pleural fluid)
AGE (ANOVA) P = 0,251 P = 0,969 P = 0,883 P = 0,067*
Primary or Metastatic (t-test) P = 0,112 P = 0,114 P = 0,015 P = 0,467
Chemotherapy or not (t-test) P = 0,127 P = 0,237 P = 0,133 P = 0,326
Type of malignancy P = 0,002 P = 0,404 P = 0,034 P = 0,593
SEX(t-test) P = 0,517 P = 0,037 P = 0,349 P = 0,773
*Was tested with multiple comparisons, no statistical significance reached.
**Three groups were used (var = Type_3_UN).
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[12] findings. Since then, numerous attempts have been
made to find out the exact role that IL-10 has to play in
the prognosis of Lung cancer. Atwell et al. [4] showed
that there is a balance between the different cytokines
excreted in patients with a thoracic malignancy. In that
concept, findings that low levels of IL-10 show bad prog-
nosis [13] could not be consistent. This led Hatanaka
et al. [14] to flag this matter up suggesting that all the
results have to be examined very carefully as the in vivo
conclusions of IL −10 action are very much different
than ex vivo – including their own results. Li Zeng et al.
[15] in 2009 stated that IL-10 promotes angiogenesis
and resistance to apoptosis thus increasing the metastatic
potential in Lung tumor cell lines. IL-10 has been
regarded as an immune suppressant cytokine [5] based
on experimental observations. Surprisingly it is thought
to have anticancer potentials [16]. This anticancer activity
of IL-10 both in animal models and human observations
was thought to be a cooperation with other factors.
Experiments showed that IL-10 administration of doses
up to 25 ug/kg had no or very little toxicity and proin-
flammatory properties. Taking all these into consideration
we can conclude that IL-10 actions are multi-factorial.
There are differences in vitro when compared to in vivo
action as well as differences regarding many other coeffi-
cients like disease stage or type of malignancy. Human
body’s response is not a standardized one when it comes
to the disease and shares a lots of common between
inflammation and wound healing. It was suggested from
the early 19th century - by Rudolf Virchow in 1963- that
cancer was linked to inflammation [17]. He noted leuco-
cytes in neoplastic tissues and made the assumption that
there is a connection between inflammation and cancer.
At the same time, he suggested that the “lymphoreticular
infiltrate” indicated the site of the primary origin. In the
last decade this theory is coming back to light, adding
more and more scientific knowledge that chronic inflam-
mation predisposes to tumor progressionand chemokines
network is very likely that it contributes very much to this
process [18]. More and more papers are trying to linkinflammation and cancer again [17,19]. Nowadays,
“subthreshold neoplastic states” caused by carcinogens as
Peyton Rous first recognised from 1941 [20], are called
“initiation” and “promotion” [21]. Cytokines might also
help as our “biochemical microscope” in detecting and
identifying malignancies.
Interleukin 17 (IL-17) is a cytokine secreted in large
amounts exclusively by T-cells upon activation. Data
available in vivo have supported both the proinflammatory
and the hematopoietic activities of Il-17 e.g. in vivo intratra-
cheal instillation of hiL-17 increased levels of rat macro-
phage inflammatory protein 2 (rMIP-2) in bronchoalveolar
lavage (BAL) which selectively recruited neutrophils into
rat airways [22]. No IL-17 has been detected in biological
fluids under normal conditions. Biologically active IL-17 is
spontaneously present in the supernatant from rheumatoid
arthritis synovium pieces but not from osteoarthritis syno-
vium, which contains a reduced T cell infiltrate [23]. The
physiological functions of Il-17 remain to be established,
in vitro and mouse in vivo data indicate that IL-17 might
play a central role in several inflammatory diseases known
to involve activated CD4+ T cells. IL-17 is now thought to
have an active involvement in inducing and mediating
proinflammatory responses. Overproduction of IL-17 has
been associated with several chronic disease conditions,
suggesting a role in the diseases [24]. This association of
several members of this family with inflammation and the
induction of other cytokines that impact the inflammatory
response suggest that there may be therapeutic use in the
blocking or regulating of the function of these proteins. Till
now, to our knowledge, IL-17 has never been measured in
malignant pleural effusions. The fact that IL-17 has been
detected elevated in both pleural fluid and blood in patients
with malignant pleural effusions shows a clear indication
that inflammation and cancer are close -if not the same-
pathways. Bibliography is enriched every day with papers
suggesting the above, further research is needed.
Conclusion
Elevated levels of inflammation related cytokines 10 and
17 in patients with malignant pleural effusions, is another
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ways are not only parallel ones but also at some points
interconnecting ones also. They could be useful tools in
understanding the pathophysiology of cancer but also a
possible beginning in having a less invasive method - a so
called "biochemical microscope"- in order to establish the
diagnosis and the histology of a malignancy. Without any
doubt further research is needed.
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